Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Amneal Pharmaceuticals Inc (AMRX)

303 + Investors. Track Smart Money conviction in AMRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -6
Streak
1Q ▼
Buyers last Q
57%

Smart Money Signals — AMRX

Based on 309 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their AMRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (98% of max)

98% of all-time peak
309 hedge funds hold AMRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +33% more funds vs a year ago

fund count last 6Q
+77 new funds entered over the past year (+33% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 57% buying

188 buying142 selling
Last quarter: 188 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-29 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 41 → 57 → 80 → 51. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

43% of holders stayed for 2+ years

■ 43% conviction (2yr+) ■ 26% medium ■ 31% new
133 out of 309 hedge funds have held AMRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +53% but shares only +5% — price-driven

Value
+53%
Shares
+4%
Last quarter: the total dollar value of institutional holdings rose +53%, but actual share count only changed +5%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

32 → 41 → 57 → 80 → 51 new funds/Q
New funds entering each quarter: 41 → 57 → 80 → 51. A growing number of institutions are discovering AMRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 51% veterans vs 38% newcomers

■ 51% veterans ■ 11% 1-2yr ■ 38% new
Entry-cohort mix of 311 holders: 159 (51%) are 2+ year veterans, 35 entered 1–2 years ago, and 117 (38%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 54% AUM from top-100 funds

54% from top-100 AUM funds
55 of 308 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in AMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.2
out of 10
Moderate Exit Risk
Exit risk score 4.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — AMRX

In 2026 Q2, 188 hedge funds were net buyers of AMRX (51 opened a new position, 137 added to an existing one), while 142 reduced or exited (85 trimmed, 57 sold completely) — a 57% buyer ratio, indicating a slight buying edge. 54% of total institutional value in AMRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -6 funds (more exits than new entries). Total institutional holders: 309.

Hedge Fund Ownership: AMRX

How many hedge funds hold AMRX — quarterly history vs. share price
Quarterly hedge fund ownership of AMRX vs. share price

Market Analysis: AMRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AMRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Amneal Pharmaceuticals Inc (AMRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AMRX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 80d ago
AMRX
+5.1%
XLV
+6.4%

AMRX outperformed XLV by -1.3% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 35d ago
AMRX
+0.2%
XLV
+0.9%

Since the filing became public, AMRX outperformed XLV by -0.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

17 top-rated funds 1 high-conviction
Consensus
5.5
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: AMRX
303 + Investors

Track Smart Money conviction in AMRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 303 315 -3.81%
13F Shares 162M 159M 1.98%
Total Value $2.74B $1.92B 42.28%
New Positions 48 80 -32
Increased Positions 136 115 +21
Closed Positions 59 38 +21
Reduced Positions 82 77 +5
Total Calls 3 1 200.0%
Total Puts 0 2 -100.0%
PUT/CALL Ratio 0.0 2.0 Bullish

Statistics: AMRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

303 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AMRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 AMRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Westshore Wealth, LLC 7.34% 1,366,274 $23.7M
2 Tpg GP A, LLC 4.27% 12,328,767 $213.4M
3 Tucker Asset Management LLC 3.76% 1,011,064 $12.6M
4 Quartz Partners, LLC 2.59% 456,091 $7.9M
5 Phocas Financial Corp. 1.97% 819,476 $14.2M
6 BlackBarn Capital Partners LP 1.90% 1,300,000 $22.5M
7 Rubric Capital Management LP 1.61% 10,168,660 $176.0M
8 RPg Family Wealth Advisory, LLC 1.35% 377,090 $6.5M
9 Nantahala Capital Management, LLC 1.31% 2,268,751 $39.3M
10 Penn Capital Management Company, LLC 1.30% 1,181,176 $20.5M
11 Parkman Healthcare Partners LLC 0.96% 541,190 $9.4M
12 PFM Health Sciences, LP 0.71% 480,715 $8.3M
13 Convergence Investment Partners, LLC 0.57% 344,765 $6.0M
14 Informed Momentum Co LLC 0.52% 337,663 $5.8M
15 Odyssean, LLC 0.52% 183,507 $3.2M
16 Globeflex Capital L P 0.32% 146,508 $2.5M
17 Hillsdale Investment Management Inc. 0.26% 649,179 $11.2M
18 Virtus Advisers, LLC 0.24% 36,823 $637K
19 Oliver Luxxe Assets LLC 0.21% 84,217 $1.5M
20 Voleon Capital Management LP 0.15% 486,052 $8.4M
21 Ares Systematic Credit Ltd 0.14% 12,978 $225K
22 Nfj Investment Group, LLC 0.13% 218,294 $3.8M
23 Paralel Advisors LLC 0.12% 185,831 $3.2M
24 Brucke Financial, Inc. 0.12% 15,300 $265K
25 Martingale Asset Management L P 0.12% 283,033 $4.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Amneal Pharmaceuticals Inc (AMRX)

What does the Smart Money Trend signal show for AMRX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their AMRX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for AMRX?

Slight buying edge — 57% buying: Last quarter: 188 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for AMRX holders?

Elite ownership — 54% AUM from top-100 funds: 55 of 308 holders are among the 100 largest funds by AUM, controlling 54% of total institutional value in AMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held AMRX?

43% of holders stayed for 2+ years: 133 out of 309 hedge funds have held AMRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Amneal Pharmaceuticals Inc (AMRX) following the 2026 Q2 hedge fund 13F filings?

As of today, AMRX has moved +0.2% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.9% for the XLV sector ETF — an outperformance of -0.7%. Since the quarter end (June 30, 2026), AMRX has gained +5.1% vs +6.4% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →